(2) ICAAM – Instituto de Ciências Agrárias e Ambientais Mediterrâneas – Universidade de Évora
(3) Faculty of Veterinary Medicine, University of Lisbon (FMV/ULisboa)
(4) Interdisciplinary Centre for Research in Animal Health (CIISA) – University of Lisbon, (FMV/ULisboa)
(5) Anjos of Assis Veterinary Medicine Centre (CMVAA)
João Carlos Alves (2)
Ana Santos (1)
Patrícia Jorge (1)
Catarina Lavrador (2)
L. Miguel Carreira (3)
L. Miguel Carreira (4)
L. Miguel Carreira (5)
The goal of this study was to describe the use and effectiveness of intra-articular MPA and TA in the management of naturally occurring hip osteoarthritis (OA) in an animal model. Twenty police working dogs were divided in two groups according to the drug administered through intra-articular (IA) injection: GT (20mg of triamcinolone acetonide – TA, per hip joint) and GMPA (40mg of methylprednisolone acetate – MPA, per hip joint). Seven different time points were considered during the study for data collection purposes: T0 (before treatment), T1 (15 days after treatment), T2, T3, T4, T5, T6, and T7 (1, 2, 3, 4, 5 and 6 months after treatment respectively). Response to treatment was measured using the Canine Brief Pain Inventory (CBPI) and Hudson Visual Analogue Scale (HVAS). Significant results were considered when p<0.05.
Treatment successfully reduced pain interference scores (PSS) in two animals of GT at T1 (20%), three at T2-T3 (37.5%) and two at T4-T7 (28.6%). For GMPA, treatment was successful in two animals at T1 (20%), four at T2 (40%), three at T3 (30%) and two at T4-T5 (20%). Considering pain interference score (PIS), treatment was a success in two animals in both GTA and GMPA from T1-T7. However, no significant differences were registered when comparing each time point with T0 at T1 nor between groups. No significant differences were registered with HVAS.
IA TA and MPA may be a treatment option for dogs with naturally occurring OA. Still, further studies are required.
BIBLIOGRAFÍA
1. Anderson KL, O’Neill DG, Brodbelt DC, et al. Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018;8(1):5641. doi:10.1038/s41598-018-23940-z.
2. Meeson RL, Todhunter RJ, Blunn G, Nuki G, Pitsillides AA. Spontaneous dog osteoarthritis — a One Medicine vision. Nat Rev Rheumatol. April 2019. doi:10.1038/s41584-019-0202-1.
3. Sieker JT, Ayturk UM, Proffen BL, Weissenberger MH, Kiapour AM, Murray MM. Immediate Administration of Intraarticular Triamcinolone Acetonide After Joint Injury Modulates Molecular Outcomes Associated With Early Synovitis. Arthritis Rheumatol. 2016;68(7):1637-1647. doi:10.1002/art.39631.
4. Centeno LM, Moore ME. Preferred intraarticular corticosteroids and associated practice: A survey of members of the American College of Rheumatology. Arthritis Care Res (Hoboken). 1994;7(3):151-155. doi:10.1002/art.1790070309.
5. Reid J, Scott M, Nolan A, Wiseman-Orr L. Pain assessment in animals. In Pract. 2013;35(2):51-56. doi:10.1136/inp.f631.
6. Brown DC, Boston RC, Coyne JC, Farrar JT, Brief C, Inventory P. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278-1283. http://www.ncbi.nlm.nih.gov/pubmed/19180716.
7. Hudson JT, Slater MR, Taylor L, Scott HM, Kerwin SC. Assessing repeatability and validity of a visual analogue scale questionnaire for use in assessing pain and lameness in dogs. Am J Vet Res. 2004;65(12):1634-1643. doi:10.2460/ajvr.2004.65.1634.
8. Brown DC, Bell M, Rhodes L. Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. Am J Vet Res. 2013;74(12):1467-1473. doi:10.2460/ajvr.74.12.1467.
9. Alves JC, Santos AM, Jorge PI. Effect of an Oral Joint Supplement When Compared to Carprofen in the Management of Hip Osteoarthritis in Working Dogs. Top Companion Anim Med. 2017;32(4):126-129. doi:10.1053/j.tcam.2017.10.003.
10. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137-162. doi:10.1016/j.joca.2007.12.013.
